Bagó is an Argentine pharmaceutical company headquartered in Buenos Aires, founded in 1940. The company has established itself as a leading manufacturer of medications for neurological and psychiatric disorders, cardiovascular diseases, oncology, and gastroenterology, with significant presence across Latin America, the Middle East, North Africa, and Southeast Asia.
Founded during a period of rapid pharmaceutical development in Argentina, Bagó has grown from a local pharmacy operation to one of the most recognized pharmaceutical brands in Latin America. The company's commitment to research, quality manufacturing, and accessible pricing has made it a trusted name in healthcare throughout the region.
Bagó was founded in 1940 by Dr. Eduardo L. Bagó, a pharmacist who established the company originally as a small laboratory in Buenos Aires. The company's early focus was on producing high-quality pharmaceutical preparations that were accessible to the Argentine population.
During the early decades, Bagó established:
- Basic manufacturing capabilities for tablets and capsules
- Quality control systems inspired by European pharmaceutical standards
- A distribution network throughout Argentina
- Early research and development operations
The mid-to-late 20th century saw significant expansion:
- Product portfolio expansion: From basic pharmaceuticals to specialty therapeutic areas
- Manufacturing modernization: Investment in new technology and production facilities
- Regional expansion: Entry into neighboring Latin American markets
- Therapeutic area development: Entry into cardiology, oncology, and CNS
Following Argentina's economic liberalization in the 1990s, Bagó:
- Strengthened its position in the generics market
- Developed innovative proprietary products
- Expanded international presence beyond Latin America
- Achieved international quality certifications
| Attribute |
Details |
| Headquarters |
Buenos Aires, Argentina |
| Founded |
1940 |
| Type |
Private pharmaceutical company |
| Focus Areas |
CNS, Cardiology, Oncology, Gastroenterology, Immunology |
| Export Markets |
45 countries worldwide |
| Products |
250+ pharmaceutical products |
| Employees |
2,500+ |
Bagó operates comprehensive manufacturing facilities in Buenos Aires:
- Oral Solid Dosage: High-speed tablet and capsule production lines
- Liquid Forms: Syrups, suspensions, solutions, and drops
- Parenterals: Injectable solutions, including sterile production
- Topical Products: Creams, ointments, gels, and transdermal patches
- Biological: Limited capacity for biotech products
- GMP Compliance: Full compliance with international Good Manufacturing Practice standards
- ISO Certifications: ISO 9001:2015, ISO 14001, and sector-specific certifications
- Regulatory Compliance: ANMAT (Argentina), FDA-equivalent standards for export
- Continuous Monitoring: Real-time quality control throughout production
- Annual tablet production: Billions of units
- Capsule production: Hundreds of millions
- Liquid formulations: Millions of liters
- Injectable production: Millions of units
Bagó provides comprehensive medications for neurodegenerative diseases, serving as a critical supplier throughout Latin America.
Bagó offers the complete spectrum of Alzheimer's disease treatments:
- Donepezil: Available in 5mg and 10mg tablets
- Rivastigmine: Oral capsules and transdermal patch formulations
- Galantamine: Immediate and extended-release formulations
These medications represent the cornerstone of AD symptomatic treatment, providing cognitive benefits by increasing synaptic acetylcholine levels through acetylcholinesterase inhibition.
- Memantine: Available as monotherapy or in fixed-dose combinations with donepezil
Memantine is indicated for moderate to severe AD, providing neuroprotective effects through NMDA receptor modulation.
- Donepezil + Memantine: Combined formulation for advanced disease stages
- Benefits include simplified dosing and improved adherence
Bagó manufactures the full range of anti-Parkinsonian medications:
| Product |
Formulation |
Description |
| Levodopa/Carbidopa |
Immediate-release |
Standard formulation |
| Levodopa/Carbidopa CR |
Controlled-release |
Extended-release for smoother dopaminergic stimulation |
| Levodopa/Carbidopa/Entacapone |
Triple combination |
Levodopa + peripheral inhibitor |
| Levodopa/Carbidopa |
Dispersible |
For patients with dysphagia |
Levodopa remains the gold standard for PD motor symptom control, and Bagó ensures broad access to these essential medications.
- Pramipexole: Non-ergot dopamine agonist for early and advanced PD
- Bromocriptine: Traditional dopamine agonist
- Cabergoline: Long-acting dopamine agonist
- Selegiline: Irreversible MAO-B inhibitor
- Rasagiline: Once-daily reversible MAO-B inhibitor
- Entacapone: Peripheral COMT inhibitor to extend levodopa effect
- Tolcapone: Central and peripheral COMT inhibitor
¶ Neuropathic Pain and Peripheral Neuropathy
Bagó manufactures medications for diabetic neuropathy and neuropathic pain, common comorbidities in neurodegenerative disease:
- Gabapentin: Calcium channel modifier for neuropathic pain
- Pregabalin: Enhanced bioavailability gabapentinoid
- Duloxetine: Serotonin-norepinephrine reuptake inhibitor for neuropathic pain
Comprehensive antiepileptic portfolio:
- Carbamazepine: Sodium channel blocker
- Valproic acid: Broad-spectrum antiepileptic
- Levetiracetam: Novel mechanism
- Lamotrigine: Sodium channel blocker
- Topiramate: Multiple mechanism antiepileptic
Bagó's neurology/psychiatry portfolio includes:
- Antidepressants: SSRIs (sertraline, fluoxetine, escitalopram), SNRIs (venlafaxine), tricyclics
- Anxiolytics: Alprazolam, clonazepam, buspirone
- Antipsychotics: Haloperidol, risperidone, olanzapine (for PD psychosis)
- Sleep medications: Melatonin, zolpidem, doxepin
¶ Research and Development
Bagó maintains active R&D operations:
- Generic drug development with bioequivalence studies
- Formulation development for improved bioavailability
- Novel delivery systems (extended-release, transdermal)
- Combination products
- CNS: Continued investment in neurological and psychiatric drugs
- Cardiovascular: Hypertension, heart failure, anticoagulation
- Oncology: Generic cancer medications
- Gastroenterology: Acid-related disorders, IBD
- Partnerships with Argentine universities
- Clinical trial execution partnerships
- Medical education support
Bagó exports to 45 countries across multiple regions:
- Direct presence in major markets
- Distribution partnerships extending reach
- Local regulatory approvals in each country
¶ Middle East and North Africa
- Established presence in Saudi Arabia, UAE, Egypt
- Registration in multiple regional markets
- Presence in Philippines, Vietnam, Thailand
- Distribution partnerships
- Selective presence in Eastern Europe
- Export to select African markets
- One of the top 10 pharmaceutical companies by revenue
- Leading position in CNS medications
- Major supplier to public healthcare system
- Strong retail presence
- Recognized as reliable regional pharmaceutical supplier
- Brand trust built over 80+ years
- Competitive pricing with quality assurance
- Local manufacturing: Reduced costs and supply chain security
- Established brand: 80+ years of market presence
- Regional distribution: Proven track record in Latin America
- Quality reputation: International certification standards
- ANMAT registration and compliance
- GMP inspections and certifications
- Pharmacovigilance obligations
- Advertising and promotional compliance
- Country-specific registration processes
- ICH guideline compliance where applicable
- Local regulatory affairs representatives
- Medication donations to public programs
- Patient assistance programs
- Support for rare disease medications
- Medical education for healthcare professionals
- Support for medical conferences
- University partnerships
- Environmental sustainability initiatives
- Local community support
- Employee volunteer programs